The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Quantification Of Antigen Presentation To CD8 T Cells During Virus Infection
Funder
National Health and Medical Research Council
Funding Amount
$582,072.00
Summary
Knowledge of how virus-infected cells are detected by the bodyÍs immune system is fundamental to our understanding of virus infections and attempts to improve vaccines. We know that many proteins are displayed during virus infection but until now, the precise details of this display have only been worked out for very few proteins, studied one at a time. In this project we will apply cutting-edge technology to gain the first holistic view of how a virus-infected cell looks to the immune system.
Host Genes Controlling Flavivirus Infection: New Insights And Application For Developing Highly Effective Kunjin Replicon-based Ebola Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$736,995.00
Summary
The applications is aimed at identifying new host genes controlling infection with West Nile virus and other medically important flaviviruses such as dengue and Japanese encephalitis. For this, we will use novel in vivo RNAi screening approach with virus libraries encoding artificial microRNAs (amirs) targeting whole mouse genome. We will then apply amiR technology to produce highly effective Kujniin replicon-based Ebola vaccine candidate that has shown promising results in trails in primates.
Vaccination Timeliness In Aboriginal And Non-Aboriginal Infants: Risk Factors For Delayed Vaccination And Impact On Disease Burden—a Record Linkage Study
Funder
National Health and Medical Research Council
Funding Amount
$538,183.00
Summary
Vaccination has had a significant impact, but preventable infections continue to occur, perhaps due to delayed uptake of scheduled doses. For the first time, we will link vaccination and other health records to: provide accurate estimates of the impact of vaccination; identify reasons for delayed vaccination; and quantify the expected reduction in disease burden if vaccination timeliness was improved. The study will help determine who would benefit most from efforts to improve timeliness.
A Universal Prophylactic Vaccine For Hepatitis C Virus
Funder
National Health and Medical Research Council
Funding Amount
$643,337.00
Summary
Hepatitis C Virus (HCV) infects 200 million people world wide. An effective vaccine to prevent HCV is urgently needed but must afford protection against the 7 diverse genotypes. In this project grant we aim to further define the quality of the immune response that is generated by a novel HCV vaccine candidate that generates pan-genotypic immunity, its unique structural features, and methods of manufacturing so that it can be tested in a future phase I human clinical trial.
Targeting Myeloid Cells To Restrict Gamma-herpesvirus Spread
Funder
National Health and Medical Research Council
Funding Amount
$643,152.00
Summary
Gamma-herpesviruses infect most people and cause cancers. Vaccines to date have worked poorly. We have identified a key role for myeloid cells in infection that suggests a new approach. Interferons restrict infection in some myeloid cells. We will test whether inducing interferons can make all myeloid cells restrictive and reduce chronic infection. We will test then whether myeloid-restricting antibodies can recruit the same defences to provide a basis for vaccination.
Prophylactic Vaccine Development For The Elimination Of Hepatitis C
Funder
National Health and Medical Research Council
Funding Amount
$936,752.00
Summary
A vaccine that prevents Hepatitis C is urgently needed to prevent infection and assist with global HCV elimination targets. This project grant will advance world-leading HCV vaccine candidates that generate both humoral and cellular immunity for clinical development.
Characterisation Of Anti-HBs Responses In Patients Undergoing Functional Hepatitis B Cure: Implication For Future Therapies
Funder
National Health and Medical Research Council
Funding Amount
$723,649.00
Summary
The hepatitis B virus causes liver cirrhosis and liver cancer. There is no cure for hepatitis B. However, a small number of patients can naturally rid themselves of the virus. We have identified 14 of these individuals and discovered that they have a unique immune response that is responsible for these “natural” cures. We plan to characterise this immune response and turn it into a therapeutic vaccine which can be used to cure patients who are still chronically infected.
CLINICAL RESEARCH TO UNDERSTAND ACQUIRED IMMUNITY TO DENGUE VIRUSES
Funder
National Health and Medical Research Council
Funding Amount
$841,953.00
Summary
Dengue, the commonest arboviral disease of humans, is caused by any of the four serotypes of dengue virus (DENV-1-4). This clinical research project will explore how acquired immunity to dengue viruses is expressed. The results will help dengue vaccine developers make better vaccines for use in Australian travellers and in dengue endemic countries in SE Asia.
Understanding Influenza-specific T Cell Immunity In The Indigenous Population
Funder
National Health and Medical Research Council
Funding Amount
$870,112.00
Summary
Hospitalisation and death rates from influenza are high in the Indigenous population. There is an urgent need for one-shot universal vaccine that protects against seasonal and pandemic strains. T cells recognising conserved viral regions can elicit such protection. As T cells are restricted by proteins called HLAs, variable between different ethnicities, we will define T cell regions and their HLA restrictions in the Indigenous population to propose strategies for universal T cell-based protecti ....Hospitalisation and death rates from influenza are high in the Indigenous population. There is an urgent need for one-shot universal vaccine that protects against seasonal and pandemic strains. T cells recognising conserved viral regions can elicit such protection. As T cells are restricted by proteins called HLAs, variable between different ethnicities, we will define T cell regions and their HLA restrictions in the Indigenous population to propose strategies for universal T cell-based protective immunity and vaccine design against influenza.Read moreRead less